The U.S. stock market closed mixed Thursday, with the S&P 500 edging up less than 0.1% to end nearly flat, the Dow Jones ...

In the latest trading session, Moderna (MRNA) closed at $33.86, marking a -5.66% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.01%. Meanwhile, the Dow ...

Bayer has opened a new legal front in the long-running battles over COVID-19 vaccine technology, suing several major ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey ...

Stéphane Bancel, CEO of vaccine maker Moderna, addressed shareholders in a letter that dissected the events of 2025 while projecting a positive outlook for the company’s future in 2026 and beyond.

The futures are trading flat on Wednesday after a second strong day for Wall Street, as the Dow Jones Industrial Average hit ...

German agrichemical giant Bayer confirmed to AFP on Wednesday that it was suing American pharmaceutical firms Pfizer, Moderna and Johnson & Johnson as well as Germany's BioNTech, alleging they broke a ...

Eli Lilly is in advanced talks to acquire Ventyx Biosciences, which is developing pills for autoimmune conditions, for more ...

Moderna is up 20% YTD, with a golden cross suggesting a trend reversal. Momentum indicators make it a top 2026 pick.

Bayer has filed separate lawsuits against the creators of three COVID-19 vaccines, claiming they violated intellectual ...

Bayer has filed lawsuits in U.S. federal courts seeking a share of the revenue generated from COVID-19 vaccines sold by ...

With this in mind, let's check out my top five stocks to buy in early 2026. Four have proven their earnings strength over ...